Patents by Inventor Peter L. Barker

Peter L. Barker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phosphocholine linked prodrug derivatives
    Patent number: 7060290
    Abstract: Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and (v) (ortho or para) carbonyl-substituted aryl; and wherein the subtituent is each an independent group or linked together thereby forming a ring; and wherein X is one or more substituted or unsubstituted group containing one or more O, N, or S atom and wherein the substituent is each an independent group or linked together thereby forming a ring; and wherein the therapeutic agent is an alcohol-containing water-insoluble steroids or another alcohol containing compounds and methods to prepare such compounds.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 13, 2006
    Assignee: Supergen, Inc.
    Inventors: Bruce H. Morimoto, Peter L. Barker
  • Phosphocholine surfactants and their use
    Patent number: 6489369
    Abstract: A pharmaceutical formulation comprising a pharmaceutically active agent, which is insoluble or sparingly soluble in water and a sterol phosphocholine surfactant.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: December 3, 2002
    Assignee: SuperGen, Inc.
    Inventors: Bruce H. Morimoto, Peter L. Barker, Vincent Hernandez, Cass K. Piper
  • Cyclized peptides and their use as platelet aggregation inhibitors
    Patent number: 5384309
    Abstract: The invention in its broad aspects relates to peptide derivatives which are useful as inhibitors platelet function mediated by the GP llbllla receptor and for the prevention of thrombus formation. The compounds of this invention are shown by the following Formula I: ##STR1## and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 17, 1989
    Date of Patent: January 24, 1995
    Assignee: Genentech, Inc.
    Inventors: Peter L. Barker, John P. Burnier, Eugene D. Thorsett
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 4680391
    Abstract: New substituted azetidinones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.
    Type: Grant
    Filed: April 10, 1985
    Date of Patent: July 14, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Raymond A. Firestone, Peter L. Barker
  • 5-(2,3-Dihydro-1H-pyrrolizin-5-oyl)-2,3-dihyd ro-1H-pyrrolizine-1-alkanoic or carboxylic acids and use thereof as anti-inflammatory and analgesic agents
    Patent number: 4536512
    Abstract: New 5-(2,3-dihydro-1H-pyrrolizin-5-oyl)-, 5-(2,3-dihydro-1H-pyrrolo[2,1-b]thiazol-5-oyl)-, 5-(2,3-dihydro-1H-pyrrolo[2,1-b]imidazol-5-oyl)-, and 5-(2,3-dihydro-1H-pyrrolo[2,1-b]oxazol-5-oyl)-derivatives of substituted 2,3-dihydro-1H-pyrrolizine-1-alkanoic or carboxylic acids have been prepared. They are found to be effective inhibitors of platelet aggregation and are analgesic/anti-inflammatory agents with low ulcerogenic side effects.
    Type: Grant
    Filed: October 8, 1982
    Date of Patent: August 20, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Bruce E. Witzel, Peter L. Barker
  • 5-(2,3-Dihydro-1H-pyrrolizin-5-oyl)-2-alkanoic or carboxylic acids and analogs as anti-inflammatory and analgesic agents
    Patent number: 4533671
    Abstract: New 5-(2,3-dihydro-1H-pyrrolizin-5-oyl)-, 5-(2,3-dihydro-1H-pyrrolo[2,1-b]thiazol-5-oyl)-, 5-(2,3-dihydro-1H-pyrrolo[2,1-b]imidazol-5-oyl)-, and 5-(2,3-dihydro-1H-pyrrolo[2,1-b]oxazol-5-oyl)-pyrrole-2-alkanoic acid derivatives have been prepared. They are found to be effective inhibitors of platelet aggregation and are analgesic and anti-inflammatory agents with low ulcerogenic side effects.
    Type: Grant
    Filed: October 8, 1982
    Date of Patent: August 6, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Bruce E. Witzel, Peter L. Barker